组蛋白去乙酰化酶抑制剂Scriptaid对小鼠圆形精子注射胚胎发育能力的影响
该研究在小鼠模型中探讨组蛋白去乙酰化酶抑制剂Scriptaid能否改善圆形精子注射(ROSI)受精胚胎的发育效率。结果显示,用250 nM Scriptaid处理ROSI合子10小时可提高囊胚形成率(59% vs 38%)和出生率(40% vs 21%),并恢复部分发育相关基因表达、适度修复印记基因甲基化异常。作者认为该处理为改善临床人类ROSI效率与安全性提供了新手段,但能否应用于人类尚需进一步研究。
要点
- 250 nM Scriptaid处理ROSI小鼠合子10小时,囊胚形成率59%高于未处理组38%。
- Scriptaid处理使ROSI胚胎出生率由21%提高至40%。
- Scriptaid可恢复ROSI囊胚Oct4、Nanog、Sox2表达并适度修复H19和Snrpn印记控制区甲基化异常。
核心结论
- 用Scriptaid处理ROSI小鼠合子可提高囊胚期多个发育相关基因表达,使囊胚体外发育更高效并提高ROSI胚胎出生率。
- 作者认为Scriptaid处理为改善临床人类ROSI的效率与安全性提供了新手段,但能否应用于人类尚需进一步研究。
研究设计与样本
- 研究使用BDF1(C57BL/6 × DBA/2)小鼠的卵母细胞、精子和圆形精子进行实验。
- 体外发育实验将小鼠ROSI合子用不同浓度Scriptaid(0、125、250、500、1000 nM)处理不同时间(0、6、10、16、24小时),每项实验至少重复三次。
- 随后将最佳Scriptaid处理组和未处理ROSI组的囊胚分别移植入ICR代孕小鼠,与ICSI组(对照)比较体内发育。
- 评估指标包括获得合子、二细胞、四细胞、囊胚和足月后代的比率,并用实时PCR分析Oct4、Nanog、Klf4、Sox2表达,用亚硫酸氢盐处理后甲基化特异性PCR(MS-PCR)测序检测H19和Snrpn甲基化状态。
主要发现
- 体外实验显示,250 nM Scriptaid处理ROSI合子10小时使囊胚形成率(59%)显著高于未处理组(38%)。
- 体内实验显示,Scriptaid处理使ROSI胚胎出生率从21%提高至40%。
- ROSI囊胚中Oct4、Nanog和Sox2基因表达降低,最佳Scriptaid处理使其恢复至与ICSI对应组相似水平。
- Scriptaid处理适度修复了H19和Snrpn印记控制区(ICR)的异常DNA甲基化模式。
关键数值与推荐
- 最佳处理条件为250 nM Scriptaid处理10小时,该组囊胚形成率为59%,未处理ROSI组为38%。
- 最佳Scriptaid处理组ROSI胚胎出生率为40%,未处理ROSI组为21%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 由于使用人类配子进行ROSI研究的伦理限制,本研究采用小鼠模型探索Scriptaid对ROSI胚胎发育潜力的影响。
- 要确定这些发现能否应用于人类,尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can the histone deacetylase inhibitor Scriptaid improve the efficiency of the development of round spermatid injection (ROSI)-fertilized embryos in a mouse model? SUMMARY ANSWER: Treatment of ROSI mouse zygotes with Scriptaid increased the expression levels of several development-related genes at the blastocyst stage, resulting in more efficient in vitro development of the blastocyst and an increased birth rate of ROSI-derived embryos. WHAT IS KNOWN ALREADY: The full-term development of embryos derived through ROSI is significantly lower than that following ICSI in humans and other species. STUDY DESIGN, SIZE, DURATION: Oocytes, spermatozoa and round spermatids were collected from BDF1 (C57BL/6 × DBA/2) mice. For in vitro development experiments, mouse ROSI-derived zygotes were treated with Scriptaid at different concentrations (0, 125, 250, 500 and 1000 nM) and for different exposure times (0, 6, 10, 16 or 24 h). Next, blastocysts of the optimal Scriptaid-treated group and the non-treated ROSI group were separately transferred into surrogate ICR mice to compare in vivo development with the ICSI group (control). Each experiment was repeated at least three times. PARTICIPANTS/MATERIALS, SETTING, METHODS: Metaphase II (MII) oocytes, spermatozoa and round spermatids were obtained from sexually mature BDF1 female or male mice. The developmental potential of embryos among the three groups (the ICSI, ROSI and optimal Scriptaid-treated ROSI groups) was assessed based on the rates of obtaining zygotes, two-cell stage embryos, four-cell stage embryos, blastocysts and full-term offspring. In addition, the expression levels of development-related genes (Oct4, Nanog, Klf4 and Sox2) were analysed using real-time PCR, and the methylation states of imprinted genes (H19 and Snrpn) in these three groups were detected using methylation-specific PCR (MS-PCR) sequencing following bisulfite treatment. MAIN RESULTS AND THE ROLE OF CHANCE: The in vitro experiments revealed that treating ROSI-derived zygotes with 250 nM Scriptaid for 10 h significantly improved the blastocyst formation rate (59%) compared with the non-treated group (38%) and further increased the birth rates of ROSI-derived embryos from 21% to 40% in vivo. Moreover, in ROSI-derived embryos, the expression of the Oct4, Nanog and Sox2 genes at the blastocyst stage was decreased, but the optimal Scriptaid treatment restored expression to a level similar to their ICSI counterparts. In addition, Scriptaid treatment moderately repaired the abnormal DNA methylation pattern in the imprinting control regions (ICRs) of H19 and Snrpn. LARGE SCALE DATA: N/A LIMITATIONS, REASONS FOR CAUTION: Because of the ethics regarding the use of human gametes for ROSI studies, the mouse model was used as an approach to explore the effects of Scriptaid on the developmental potential of ROSI-derived embryos. However, to determine whether these findings can be applied to humans, further investigation will be required. WIDER IMPLICATIONS OF THE FINDINGS: Scriptaid treatment provides a new means of improving the efficiency and safety of clinical human ROSI. STUDY FUNDING/COMPETING INTERESTS: The study was financially supported through grants from the National Key Research Program of China (No. 2016YFC1304800); the National Natural Science Foundation of China (Nos: 81170756, 81571486); the Natural Science Foundation of Shanghai (Nos: 15140901700, 15ZR1424900) and the Programme for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning. There are no conflicts of interest to declare.
引用
- Kong P, Yin M, Chen D, et al. Effects of the histone deacetylase inhibitor 'Scriptaid' on the developmental competence of mouse embryos generated through round spermatid injection. Hum Reprod. 2016. PMID: 27864358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。